New Approach in Delivering Chemotherapy: Locoregional Treatment for Recurrent Glioblastoma (rGBM)

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4 SUPPL., 2003, Pages 123-127

  Boiardi, Amerigo ^a   Eoli, M ^a   Salmaggi, A ^a   Lamperti, E ^a   Botturi, A ^a   Broggi, G ^b   Bartolomei, M ^a   Silvani, A ^a  

^a Ist Nazionale Neurologico C Besta ^*  (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Glioblastoma recurrence; Local chemotherapy; Locoregional radioimmunotherapy; Mitoxantrone; Pegylated doxorubicin

Indexed keywords

AVIDIN; AVIDIN Y 90; DOXORUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC4; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; FEASIBILITY STUDY; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; INJECTION SITE; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUROLOGIC EXAMINATION; OSTEITIS; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENT CANCER; RECURRENT GLIOBLASTOMA; REOPERATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RADIOIMMUNOTHERAPY;

EID: 1842478671     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Walker M.D., Green S.B., Byar D.P. et al..: Randomized comparisions of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303: 1323-1327, 1980.
2. Fine H.A., Dear K.B.G., Loeffler Y.S., Black P.M.L., Canellos G.P.: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.
3. Grossman S.: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76: 640-647, 1992.
4. Brem H., Piantadossi S., Burger P., Walker M., Seiler R.W.: Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain Tumor Treatment Group. Lancet 345: 1008-12, 1995.
5. Valtonen S., Timonen U., Toivanen P. et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg. 41: 44-49, 1997.
6. Boiardi A., Salmaggi A., Pozzi A., Broggi G., Silvani A.: Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J. Neuroncol. 27: 157-162, 1996.
7. MacDonald D.R., Cascino T.L., Clifford S.: Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8: 1277-1280, 1990.
8. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5: 649-655, 1982.
9. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457-481, 1958.
10. Friedman H.S., Kerby T., Calvert H: Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6: 2585-2597, 2000.
11. Sipos E.P., Tyler B., Piantadossi S., Burger P.C., Brem H.: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol. 39: 383-389, 1997.
12. Senkal M., Tonn J.C., Schonmayr R., Schachenmayr W.: Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J. Neuroncol. 32: 203-208, 1987.
13. Gururangan S., Cokgor L., Rich J.N. et al.: Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. J. Neurooncol. 3: 246-250, 2001.
14. Brada M., Hoang-Xuan K., Rampling R. et al.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12: 149-150, 2001.
15. Riva P., Arista A., Franceschi G. et al.: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 55: 5952-5956, 1995.
16. Riva P., Franceschi G., Riva N., Casi M., Santimaria M., Adamo M.: Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur. J. Nucl. Med. 27: 601-609, 2000.
17. Paganelli G., Bartolomei M., Ferrari M. et al.: Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16: 227-235, 2001.
18. Lieberman D.M., Laske D.W., Morrison P.F., Bankiewicz K.S., Oldfield E.H.: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. Neurosurg. 82: 1021-1029, 1995.